Cargando…
Use of analgesics in France, following dextropropoxyphene withdrawal
BACKGROUND: In 2009, the European Medicines Agency recommended withdrawal of dextropropoxyphene (DXP); in March 2011 it was withdrawn from the market in France. Up until that time the combination dextropropoxyphene-paracetamol (DXP/PC) was widely used for analgesia. At withdrawal, French regulators...
Autores principales: | Van Ganse, E., Belhassen, M., Ginoux, M., Chrétien, E., Cornu, C., Ecoffey, C., Aubrun, F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880096/ https://www.ncbi.nlm.nih.gov/pubmed/29609613 http://dx.doi.org/10.1186/s12913-018-3058-1 |
Ejemplares similares
-
Perceptions of French general practitioners and patients regarding dextropropoxyphene withdrawal: a qualitative study
por: Combier, Aurélie, et al.
Publicado: (2018) -
Ban on Dextropropoxyphene is Unjustifiable
por: Butola, Savita, et al.
Publicado: (2015) -
Survival after an overdose of Distalgesic (dextropropoxyphene and paracetamol).
por: Ruane, B. J., et al.
Publicado: (1989) -
Dextropropoxyphene ban in India: Is there a case for reconsideration?
por: Balhara, Yatan Pal Singh
Publicado: (2014) -
EvaluatioN of ApiXaban in strOke and systemic embolism prevention in patients with non‐valvular atrial fibrillation in clinical practice Setting in France, rationale and design of the NAXOS: SNIIRAM study
por: Picard, Fabien, et al.
Publicado: (2019)